181 related articles for article (PubMed ID: 35281606)
1. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
Rezaei S; Assaran Darban R; Javid H; Hashemy SI
Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606
[TBL] [Abstract][Full Text] [Related]
2. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract][Full Text] [Related]
3. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
4. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
AlAlikhan A; Ghahremanloo A; Javid H; Ebrahimi S; Hashemy SI
Cell Biochem Biophys; 2022 Dec; 80(4):819-827. PubMed ID: 36197642
[TBL] [Abstract][Full Text] [Related]
6. The redox modulatory effects of SP/NK1R system: Implications for oxidative stress-associated disorders.
Ebrahimi S; Alalikhan A; Aghaee-Bakhtiari SH; Hashemy SI
Life Sci; 2022 May; 296():120448. PubMed ID: 35247438
[TBL] [Abstract][Full Text] [Related]
7. The SP/NK1R System-Mediated ROS Generation in GBM Cells through Inhibiting Glutaredoxin Protein.
Mehrabani N; Vaezi Kakhki MR; Javid H; Ebrahimi S; Hashemy SI
Neurol Res Int; 2021; 2021():9966000. PubMed ID: 34917417
[TBL] [Abstract][Full Text] [Related]
8. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic role of the SP/ NK1R system in GBM cells through inhibiting the thioredoxin system.
Ghahremani F; Sabbaghzadeh R; Ebrahimi S; Javid H; Ghahremani J; Hashemy SI
Iran J Basic Med Sci; 2021 Apr; 24(4):499-505. PubMed ID: 34094032
[TBL] [Abstract][Full Text] [Related]
10. The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells.
Korfi F; Javid H; Assaran Darban R; Hashemy SI
Biochem Res Int; 2021; 2021():6620708. PubMed ID: 33976938
[TBL] [Abstract][Full Text] [Related]
11. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
12. The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.
Zarei Shandiz S; Assaran Darban R; Javid H; Ghahremanloo A; Hashemy SI
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; ():. PubMed ID: 38334824
[TBL] [Abstract][Full Text] [Related]
13. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the Role of Neurokinin-1 Receptor Inhibition Using Aprepitant in the Apoptotic Cell Death through PI3K/Akt/NF-
Ghahremanloo A; Javid H; Afshari AR; Hashemy SI
Biomed Res Int; 2021; 2021():1383878. PubMed ID: 34395609
[TBL] [Abstract][Full Text] [Related]
15. The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells.
Momen Razmgah M; Ghahremanloo A; Javid H; AlAlikhan A; Afshari AR; Hashemy SI
Mol Biol Rep; 2022 Oct; 49(10):9307-9314. PubMed ID: 35960409
[TBL] [Abstract][Full Text] [Related]
16. The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells.
Golestaneh M; Firoozrai M; Javid H; Hashemy SI
Mol Biol Rep; 2022 Jun; 49(6):4893-4900. PubMed ID: 35429316
[TBL] [Abstract][Full Text] [Related]
17. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
18. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
Matalińska J; Świć A; Lipiński P; Misicka A
Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
[TBL] [Abstract][Full Text] [Related]
20. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]